Assertio stock faced prolonged downward pressure over time due to various fundamental headwinds, including patent expirations on key legacy products, revenue concentration risks, shifting generic competition, and broader market skepticism regarding specialty pharmaceutical margins. These operational challenges impacted net earnings and investor sentiment, ultimately preceding structural corporate shifts, valuation adjustments, and its eventual acquisition by Zydus Lifesciences.